Clinical Trial Detail

NCT ID NCT03308396
Title Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ajjai Alva, MD
Indications

clear cell renal cell carcinoma

Therapies

Durvalumab + Guadecitabine

Guadecitabine

Age Groups: adult senior

No variant requirements are available.